Literature DB >> 30923092

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.

Elena Santagostino1, Maria Elisa Mancuso2, Cristina Novembrino1, Luigi Piero Solimeno3, Armando Tripodi1, Flora Peyvandi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30923092      PMCID： PMC6669151          DOI： 10.3324/haematol.2018.215129

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.

Authors:  E Santagostino; M Morfini; A Rocino; F Baudo; F A Scaraggi; A Gringeri
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

2.  Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.

Authors:  Yesim Dargaud; Anne Lienhart; Maissaa Janbain; Sandra Le Quellec; Nathalie Enjolras; Claude Negrier
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

3.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Authors:  Johannes Oldenburg; Johnny N Mahlangu; Benjamin Kim; Christophe Schmitt; Michael U Callaghan; Guy Young; Elena Santagostino; Rebecca Kruse-Jarres; Claude Negrier; Craig Kessler; Nancy Valente; Elina Asikanius; Gallia G Levy; Jerzy Windyga; Midori Shima
Journal:  N Engl J Med       Date:  2017-07-10       Impact factor: 91.245

4.  Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.

Authors:  Yesim Dargaud; Anne Lienhart; Claude Negrier
Journal:  Blood       Date:  2010-09-01       Impact factor: 22.113

5.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

Authors:  Naoki Uchida; Takehiko Sambe; Koichiro Yoneyama; Naoki Fukazawa; Takehiko Kawanishi; Shinichi Kobayashi; Midori Shima
Journal:  Blood       Date:  2015-12-01       Impact factor: 22.113

6.  Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.

Authors:  M E Mancuso; V Chantarangkul; M Clerici; M R Fasulo; L Padovan; E Scalambrino; F Peyvandi; A Tripodi; E Santagostino
Journal:  Haemophilia       Date:  2016-05-16       Impact factor: 4.287

7.  Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.

Authors:  J Schneiderman; D J Nugent; G Young
Journal:  Haemophilia       Date:  2004-07       Impact factor: 4.287
  7 in total
  6 in total

1.  Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

Authors:  Giancarlo Castaman; Cristina Santoro; Antonio Coppola; Maria E Mancuso; Rita C Santoro; Sergio Bernardini; Francesco R Pugliese; Riccardo Lubrano; Maria Golato; Armando Tripodi; Angiola Rocino; Elena Santagostino; Chiara Biasoli; Alessandra Borchiellini; Alberto Catalano; Laura Contino; Antonella Coluccia; Dorina Cultrera; Raimondo De Cristofaro; Giovanni Di Minno; Andrea Fabbri; Massimo Franchini; Gabriella Gamba; Anna Chiara Giuffrida; Paolo Gresele; Adele Giampaolo; Hamisa J Hassan; Matteo Luciani; Emanuela Marchesini; Renato Marino; Maria Gabriella Mazzucconi; Angelo C Molinari; Massimo Morfini; Lucia D Notarangelo; Lucia Peccarisi; Flora Peyvandi; Berardino Pollio; Gianna Franca Rivolta; Maria Pia Ruggieri; Vittorio Sargentini; Mario Schiavoni; Laura Sciacovelli; Maria Luisa Serino; Sergio Siragusa; Annarita Tagliaferri; Sophie Testa; Alberto Tosetto; Stefania Zampogna; Ezio Zanon
Journal:  Blood Transfus       Date:  2019-10-18       Impact factor: 3.443

2.  Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor.

Authors:  Charles R Lefèvre; Anaïs Jaffré; Adeline Pontis; Fabienne Nedelec-Gac; Pierre Guéret; Isabelle Gouin-Thibault; Bernard Fraisse; Sophie Bayart; Benoit Guillet
Journal:  TH Open       Date:  2021-05-12

3.  Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays.

Authors:  Hande Kizilocak; Clara Lana Yukhtman; Elizabeth Marquez-Casas; Jeanie Lee; Jennifer Donkin; Guy Young
Journal:  Ther Adv Hematol       Date:  2019-06-27

Review 4.  Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review.

Authors:  Marieke J A Verhagen; Lars L F G Valke; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2022-01-28       Impact factor: 16.036

Review 5.  Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.

Authors:  Silvia Linari; Giancarlo Castaman
Journal:  Ther Clin Risk Manag       Date:  2020-05-22       Impact factor: 2.423

6.  Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.

Authors:  Hans H Brackmann; Wolfgang Schramm; Johannes Oldenburg; Viridiana Cano; Peter L Turecek; Claude Négrier
Journal:  Hamostaseologie       Date:  2020-07-27       Impact factor: 2.145
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.